Overview

Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)

Status:
Enrolling by invitation

Trial end date:
2025-07-31

Target enrollment:

Participant gender:

Summary

This open-label study will evaluate the safety of continued therapy with inhaled treprostinil in participants who have completed Study RIN-PH-304 (NCT03496623). This study hypothesizes that long-term safety findings will be similar to those observed in the randomized, placebo-controlled, double-blind, adaptive study 'A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients with Pulmonary Hypertension due to Chronic Obstructive Pulmonary Disease (PH-COPD)(RIN-PH-304).

Phase:

Phase 3

Details

Lead Sponsor:

Lung Biotechnology PBC
United Therapeutics

Collaborators:

Lung Biotechnology PBC
United Therapeutics

Treatments:

Pharmaceutical Solutions
Treprostinil